Global Study Reveals Disparities in Maternal RSV Vaccine Uptake Despite 74% Efficacy
Source Summary
A new global review shows that vaccination against respiratory syncytial virus (RSV) during pregnancy reduces the risk of severe disease in infants by 74%, yet uptake remains low in many countries. The study identifies lower vaccination rates among certain socioeconomic and ethnic groups, populations with limited healthcare access, and younger mothers.
Why it matters
The findings highlight a significant public-health gap: a highly effective vaccine exists to protect vulnerable infants from severe RSV disease, yet unequal access and uptake leave many newborns at preventable risk.
